Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product. Led by Europe and Asia, the global mAb biosimilars market is expected to witness a double-digit growth rate over 2016-2020. Europe dominates the market mainly due to an increase in the manufacture of biosimilars by European vendors as well as in the consumption of biosimilars in this region. On the other hand, the situation in the US is complicated due to the formation of a new legislative body to govern biosimilar products.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

Assumptions

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Biosimilars: Overview

Comparative analysis of generic small molecules and

biosimilars

Biosimilars market opportunities

Challenges for new entrants

Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Market segmentation by application

Global chronic and autoimmune diseases mAb

biosimilars market

Global oncology mAb biosimilars market

PART 08: Geographical segmentation

Global mAb biosimilars market by geographical

segmentation 2015-2020

mAb biosimilars market in Europe

mAb biosimilars market in Asia

mAb biosimilars market in rest of the world

PART 09: Market drivers

Rise in number of patent expiries

Need for cost-effective treatment

Reimbursement benefits for biosimilars

Favorable government regulations

PART 10: Impact of drivers

PART 11: Market challenges

Physicians' reluctance to prescribe biosimilars

Multiple manufacturing complexities

Risks related to drug failure

Limited availability of biosimilar products

Difficulties in patient recruitment for clinical trials

PART 12: Impact of drivers and challenges

PART 13: Market trends

Emergence of biosimilars

Outsourcing of manufacturing activities

Need for high investment in R&D

High growth in the emerging markets

Rising number of strategic collaborations

PART 14: Vendor landscape

Competitive scenario

PART 15: Key vendor analysis

Biocon

Celltrion

Dr. Reddy's Laboratories

Hospira

Other prominent vendors

PART 16: Appendix

List of abbreviations

PART 17: Explore Technavio